Imunon agrees to sell ThermoDox rights to VoxelDox Therapeutics
Bitget2026/10/21 12:15- Imunon agreed to sell its rights to ThermoDox, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics.
- Consideration includes an approximately 4.76% equity interest in VoxelDox and up to $16.5 million in development and sales-based milestone payments.
- Tiered royalties range from 3.5% to 6% of net sales of ThermoDox-related products, if approved.
- Closing depends on VoxelDox completing $2.5 million in financing to support a Phase 1 glioblastoma trial.
- The sale preserves potential economic participation while focusing resources on the pivotal Phase 3 OVATION 3 trial of IMNN-001 in advanced ovarian cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple plans to raise 7 billions USD to repurchase stocks, returning to the US dollar bond market after a year and a half.
Apple raised approximately $7 billion through this bond issuance, which is divided into seven tranches with maturities ranging from two to ten years. The longest tranche was initially priced at a spread of 80 basis points over US Treasuries. The proceeds from the bonds will be used for general corporate purposes, including stock buybacks, dividend payments, and capital expenditures. Analysts pointed out that shareholder returns are a higher priority than AI capital expenditures in Apple's capital allocation.
BUZZ - Sun Life Financial shares fall after Q3 earnings release
Pegasystems Wins 10-Year U.S. Army Contract Worth Up to $419 Million
BUZZ - Coffee chain Dutch Bros shares fall due to weak sales outlook
Crypto prices
More
